🔎 Trials Near Me

Почетна › Акутна миелоидна леукемија › Северна Каролина › Durham

Клинички испитувања за Акутна миелоидна леукемија во Durham, NC

33 студии за Акутна миелоидна леукемија бараат учесници на локации во и околу Durham (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Се регрутираФаза 2
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
  • Durham VA Medical Center, Durham
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Duke University Medical Center, Durham
Возраст од 18 до 59 · Сите полови · Ажурирано 28.9.2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Duke University Medical Center, Durham
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Duke University Medical Center, Durham
Возраст од 18 до 59 · Сите полови · Ажурирано 22.9.2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Duke University Medical Center, Durham
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Се регрутираФаза 3
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
6 Months – 21 Years · Сите полови · Ажурирано 17.9.2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Се регрутираФаза 1/2
  • Duke University Medical Center, Durham
30 Days · Сите полови · Ажурирано 16.9.2026 · NCT04065399

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Се регрутираФаза 1
  • University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06846606

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Се регрутираФаза 1/2
  • UNC School of Medicine, Division of Hematology, Chapel Hill · на 10 милји
Возраст 12 и постари · Сите полови · Ажурирано 3.9.2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Се регрутираФаза 3
  • US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Се регрутираФаза 1/2
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Се регрутираФаза 1
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Возраст од 18 до 75 · Сите полови · Ажурирано 25.8.2026 · NCT05886049

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Се регрутираФаза 3
  • Duke University Medical Center, Durham
  • University of North Carolina, Chapel Hill, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 20.8.2026 · NCT07007312

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Се регрутираФаза 1
  • University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT06656494

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Се регрутираФаза 1/2
  • Research Site, Durham
  • Research Site, Chapel Hill · на 10 милји
Возраст 16 и постари · Сите полови · Ажурирано 20.7.2026 · NCT07155226

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Се регрутираФаза 2
  • University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 10.7.2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Се регрутираНабљудувачка студија
  • Duke University Medical Center, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Се регрутира
  • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Возраст 60 и постари · Сите полови · Ажурирано 6.7.2026 · NCT06697600

Registry of Older Patients With Cancer

Се регрутираНабљудувачка студија
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 милји
Возраст 65 и постари · Сите полови · Ажурирано 29.6.2026 · NCT01137825

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Се регрутираФаза 2
  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 23.6.2026 · NCT05401097

A Study of Revumenib and Mezigdomide in People With Leukemia

Се регрутираФаза 1/2
  • University of North Carolina (Data Collection Only), Chapel Hill · на 10 милји
Возраст 12 и постари · Сите полови · Ажурирано 22.6.2026 · NCT07356154

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Се регрутираФаза 1
  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Возраст 18 и постари · Сите полови · Ажурирано 14.5.2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Се регрутираФаза 1
  • University of North Carolina, Chapel Hill · на 10 милји
Возраст 13 и постари · Сите полови · Ажурирано 5.5.2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Се регрутираФаза 2/3
  • Duke University, Durham
Возраст 18 и постари · Сите полови · Ажурирано 30.4.2026 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Се регрутираФаза 1/2
  • Duke University, Durham
  • UNC Hospital, Chapel Hill · на 10 милји
Возраст 12 и постари · Сите полови · Ажурирано 24.3.2026 · NCT04988555

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Се регрутираФаза 2
  • University of North Carolina, Chapel Hill · на 10 милји
Возраст од 18 до 66 · Сите полови · Ажурирано 17.3.2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Се регрутираФаза 1
  • Duke Blood Cancer Center, Durham
Возраст 18 и постари · Сите полови · Ажурирано 13.3.2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Се регрутираФаза 1
  • Duke Cancer Center, Durham
Возраст 18 и постари · Сите полови · Ажурирано 16.1.2026 · NCT05143996

Novel Digital Application for Patients With Acute Leukemia

Се регрутира
  • Duke University, Durham
Возраст од 18 до 120 · Сите полови · Ажурирано 10.11.2025 · NCT06472128

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Се регрутираНабљудувачка студија
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 милји
Возраст од 18 до 120 · Сите полови · Ажурирано 27.10.2025 · NCT01137643

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Се регрутираФаза 1/2
  • Duke University Medical Center, Durham
Возраст 18 и постари · Сите полови · Ажурирано 26.8.2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Се регрутираДобредојдени се здрави волонтери
  • Duke University, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
Возраст од 18 до 120 · Сите полови · Ажурирано 25.7.2025 · NCT05237258

Испитувања за Акутна миелоидна леукемија во други градови

Други студии во Durham

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.